ADAURA 能否做得更好？完善全球研究实践以减少癌症护理差距。
Could We Have Improved on ADAURA? Refining Global Research Practices to Reduce Cancer Care Disparities.
机构信息
Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA.
AccessHope, Los Angeles, CA.
出版信息
JCO Glob Oncol. 2023 Sep;9:e2300344. doi: 10.1200/GO.23.00344.
Abstract
ADAURA was a positive trial, but could changes have improved it and reduced global care disparities?
摘要
ADAURA 是一项阳性试验，但有没有可能通过改变来改善它并减少全球护理差距？
相似文献
1
Could We Have Improved on ADAURA? Refining Global Research Practices to Reduce Cancer Care Disparities.ADAURA 能否做得更好？完善全球研究实践以减少癌症护理差距。
JCO Glob Oncol. 2023 Sep;9:e2300344. doi: 10.1200/GO.23.00344.
2
Psychological Safety in the Medical Care of Black Breast and Ovarian Cancer Patients and Families.黑人乳腺癌和卵巢癌患者及其家庭医疗护理中的心理安全感
Psychooncology. 2025 Mar;34(3):e70127. doi: 10.1002/pon.70127.
3
Stakeholders' perceptions and experiences of factors influencing the commissioning, delivery, and uptake of general health checks: a qualitative evidence synthesis.利益相关者对影响一般健康检查的委托、提供和接受因素的看法与体验：一项定性证据综合分析
Cochrane Database Syst Rev. 2025 Mar 20;3(3):CD014796. doi: 10.1002/14651858.CD014796.pub2.
4
Defining Practice Capacity for Cancer Care Delivery to Adolescents and Young Adults in the Community Setting: 2022 Landscape Assessment Results.定义社区环境下为青少年和青年癌症患者提供护理的实践能力：2022 年景观评估结果。
J Adolesc Young Adult Oncol. 2024 Jun;13(3):557-563. doi: 10.1089/jayao.2023.0177. Epub 2024 Feb 23.
5
Interventions for fertility preservation in women with cancer undergoing chemotherapy.对接受化疗的癌症女性进行生育力保存的干预措施。
Cochrane Database Syst Rev. 2025 Jun 19;6:CD012891. doi: 10.1002/14651858.CD012891.pub2.
6
Proposed Policy Changes to Cancer Care and Oncologic Drug Reimbursement: Exploring the Rationale and Anticipating the Consequences.
Am Soc Clin Oncol Educ Book. 2025 Jun;45(3):e473822. doi: 10.1200/EDBK-25-473822. Epub 2025 Jun 17.
7
"There's just such a mismatch": a qualitative exploration of health systems and organizational-level barriers to accessing cancer services among people experiencing structural marginalization.“存在如此严重的不匹配”：对经历结构性边缘化的人群在获取癌症服务方面的卫生系统和组织层面障碍的定性探索。
Int J Equity Health. 2025 Jun 18;24(1):181. doi: 10.1186/s12939-025-02554-8.
8
Addressing Cancer Disparities in SGM Populations: Recommendations for a National Action Plan to Increase SGM Health Equity Through Researcher and Provider Training and Education.解决性取向和性别认同少数群体中的癌症差异：通过研究人员和医疗服务提供者培训与教育提高性取向和性别认同少数群体健康公平性的国家行动计划建议。
J Cancer Educ. 2020 Feb;35(1):44-53. doi: 10.1007/s13187-018-1438-1.
9
Global therapeutic mobilities and cancer: a scoping review.全球治疗性流动与癌症：一项范围综述
BMJ Open. 2025 Jun 18;15(6):e089780. doi: 10.1136/bmjopen-2024-089780.
10
Disparities in cancer care: Are we making progress?: a look at how researchers and organizations are working to reduce cancer health disparities.癌症护理中的差异：我们正在取得进展吗？：审视研究人员和组织如何努力减少癌症健康差异。
Cancer. 2012 Feb 15;118(4):867-8. doi: 10.1002/cncr.27436.
本文引用的文献
1
Overall Survival with Osimertinib in Resected -Mutated NSCLC.奥希替尼治疗可切除突变型 NSCLC 的总生存期。
N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4.
2
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.辅助奥希替尼治疗 EGFR 突变型 IB-IIIA 期非小细胞肺癌：III 期随机 ADAURA 试验的更新结果。
J Clin Oncol. 2023 Apr 1;41(10):1830-1840. doi: 10.1200/JCO.22.02186. Epub 2023 Jan 31.
3
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With Exon 19 Deletion or L858R Mutations.AENEAS：奥莫替尼对比吉非替尼一线治疗局部晚期或转移性非小细胞肺癌伴 exon19 缺失或 L858R 突变的随机 III 期研究。
J Clin Oncol. 2022 Sep 20;40(27):3162-3171. doi: 10.1200/JCO.21.02641. Epub 2022 May 17.
4
Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.辅助 EGFR-TKIs 治疗可切除非小细胞肺癌的疗效和安全性：基于随机对照试验的系统评价和荟萃分析。
BMC Cancer. 2022 Mar 26;22(1):328. doi: 10.1186/s12885-022-09444-0.
5
Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China.本土研发的仿制药能否助力价格谈判？以中国的癌症治疗药物为例。
Semin Oncol. 2021 Apr;48(2):141-144. doi: 10.1053/j.seminoncol.2021.03.001. Epub 2021 Apr 6.
6
Why Not Adore ADAURA?-The Trial We Need vs the Trial We Got.为何不推崇ADAURA试验？——我们需要的试验与我们得到的试验。
JAMA Oncol. 2021 May 1;7(5):677-678. doi: 10.1001/jamaoncol.2020.6752.
7
Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.奥希替尼治疗未经治、-突变型晚期 NSCLC 的总生存期。
N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.
8
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.奥希替尼治疗未经治疗的 EGFR 突变型晚期非小细胞肺癌。
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
Zotero 插件